(Q36793605)

16 August 2017

1 reference

title

Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents (English)

1 reference

16 August 2017

0 references

1 reference

W T Cefalu

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

published in

1 reference

16 August 2017

volume

81

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

636-649

1 reference

Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Metformin and free fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Tissue triglyceride levels in type 2 diabetes and the role of thiazolidinediones in reversing the effects of tissue hypertriglyceridemia: review of the evidence in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Individual sulfonylureas and serious hypoglycemia in older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Narrative review: a rational approach to starting insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

The burden of mortality attributable to diabetes: realistic estimates for the year 2000

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

The natural history of type 2 diabetes. Implications for clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Combining sulfonylureas and other oral agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Current therapeutic options in type 2 diabetes mellitus: a practical approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

1 reference

7 January 2021

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Role of AMP-activated protein kinase in mechanism of metformin action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

1 reference

7 January 2021

Clinical review of glimepiride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Insulin secretagogues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Glucagon: the effects of its excess and deficiency on insulin action.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

GLP-1 based therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

1 reference

7 January 2021

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Banting lecture 1990. Beta-cells in type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Point: Pulmonary inhalation of insulin: another "brick in the wall"

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Evolving strategies for insulin delivery and therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100156

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100156

1 reference

Dimensions Publication ID

16 August 2017

1021157881

0 references

1 reference